Harpoon Therapeutics, Inc. 3 SEC Filings

Filed On	Filing
17 Jan 2024	Form 3: Merck & Co., Inc., 10% owner and 1 other Holds 0 shares of Common Stock, par value $0.0001
26 Dec 2023	Form 3: Bucher James B, Chief Legal Officer No securities owned
27 Mar 2023	Form 3: New Leaf Biopharma Opportunities II, L.p., 10% owner and 6 others Holds 10,000 shares of 8.000% Series A Redeemable Preferred Stock
04 Oct 2022	Form 3: Walker Luke Nathaniel, Chief Medical Officer Holds 0 shares of No securities are beneficially owned
19 Sep 2022	Form 3: Lanza Frank J, Principal Fin. & Acctng Ofc. Holds 6,540 shares of Common Stock
19 Sep 2022	Form 3: Silvernail Lauren P, Director Holds 0 shares of No securities are beneficially owned
26 Mar 2021	Form 3: Colowick Alan, Director No securities owned
02 Jul 2020	Form 3: Viney Joanne L., Director No securities owned
01 Apr 2020	Form 3: Bailes Joseph S, Director No securities owned
01 Apr 2020	Form 3: Robbins Andrew R, Director No securities owned
07 Feb 2019	Form 3: Arix Bioscience plc, 10% owner and 1 other
07 Feb 2019	Form 3: Myers Scott Dunseth, Director Holds 27,656 shares of Common Stock
07 Feb 2019	Form 3: New Leaf Ventures III, L.p., 10% owner and 5 others
07 Feb 2019	Form 3: Mpm BioVentures 2014, L.p., 10% owner and 6 others Holds 322,063 shares of Common Stock
07 Feb 2019	Form 3: Hunt Ronald, Director
07 Feb 2019	Form 3: Gadicke Ansbert, 10% owner Holds 322,063 shares of Common Stock
07 Feb 2019	Form 3: Eastland Julia Marie, Director
07 Feb 2019	Form 3: Ubs Oncology Impact Fund L.p., 10% owner and 3 others
07 Feb 2019	Form 3: Drachman Jonathan G, Director
07 Feb 2019	Form 3: Chin Mark, Director

Comments